DAC group is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Diet Dietary restriction and supplementation are key measures taken in several well-known metabolic disorders, including galactosemia, phenylketonuria (PKU), maple syrup urine disease, organic acidurias and urea cycle disorders. Such restrictive diets can be difficult for the patient and family to maintain, and require close consultation with a nutritionist who has special experience in metabolic disorders. The composition of the diet will change depending on the caloric needs of the growing child and special attention is needed during a pregnancy if a woman is affected with one of these disorders.
Optical spectrometry, a technique for measuring the distribution of light across the optical spectrum, from the ultraviolet spectral region to the visible and infrared Ion-mobility spectrometry, an analytical technique used to separate and identify ionized molecules in the gas phase based on their ion mobility in a carrier buffer gas Mass spectrometry, an analytical technique that measures the mass-to-charge ratio of charged particles Rutherford backscattering spectrometry, an analytical technique used to determine the structure and composition of materials by measuring the back-scattering of a beam of high energy ions impinging on a sample Neutron triple-axis spectrometry, a technique used in inelastic neutron scattering Gamma-spectrometry, a method used to acquire a quantitative gamma-spectrum measurement Nuclear magnetic resonance spectroscopy, a technique that uses radio frequency pulses and a magnetic field to study the properties of atomic nuclei.
In the late-1970s, Ruben Rausing worked on Operation Flood, a joint venture between the World Food Programme, the World Bank, and Tetra Pak to supply Western milk surplus to Indian households. The company established its Food for Development office in 2000, through which it works with local governments, NGOs and farmers to develop school milk programmes, a cause it has supported since 1962, when the first school milk programme supported by Tetra Pak launched in Mexico. After the 2008 Chinese melamine scandal, the Chinese government tightened regulations on safety and environmental standards, damaging the country's market for packaged milk and infant formula. Tetra Pak had nothing to do with the scandal; however, Tetra Pak China established a training program that was delivered by a food safety school, DVDs, and books, resulting in over 30 farms meeting EU quality standards, according to Tetra Pak China. The effort also included a push to reduce waste by advising customers on recycling and working alongside the World Wildlife Fund to reduce carbon dioxide emissions. The Financial Times indicated this was not a philanthropic act, but a way to establish a future for the company by ensuring there was always a market for their products. In 2015, Tetra Pak in collaboration with DeLavel, signed a five-year agreement with the Dairy Association of China to provide training to 150 Chinese dairy farm managers, providing them with the skills required to run larger-scale dairy farms. It is unclear if this initiative was voluntary or paid for.
Sources: en.wikipedia.org
=== Sportspeople === Cyclist and Olympic gold medalist Anna Meares said "Unfair, unsafe – I just don't think this is the right way to go about sport." Cyclist Joseph M. Papp, suspended for doping in 2006, referred to a 1988 Weekend Update skit, saying: "I don't think you'd actually see guys tearing their arms off ... A doping free-for-all just invites the most ambitious person to be the most reckless person, and to take the most drugs possible without literally killing themselves." Badminton player Susan Egelstaff stated, "It cannot, and will not work. The danger is massive." Swimmer and Olympic gold medalist Leisel Jones stated that while she would not participate herself due to the risks, she'd be interested in how fast people could get with doping, saying: "If this clears out people who ... are doing illegal things in sport, if that clears them out our clean sport, that would be wonderful." Swimmer and Olympic gold medalist Libby Trickett said it was understandable TEG would attract fascination and interest, and that "I really, really, really hope that it's done under medical supervision because that's the only way I can kind of justify in my head something like this to go ahead." Olympic swimmer Mark Foster expressed similar views, noting also that money has attraction.
Typical antipsychotics Chlorpromazine Haloperidol Haloperidol functions by blocking the KCNH2 channel, the same pathway that other drug-inducing LQTS block. Patients taking haloperidol are at a higher risk if they also have electrolyte abnormalities (such as hypokalemia and/or hypomagnesemia), congenital LQTS, cardiac abnormalities, hypothyroidism, or if they are concurrently taking other medications known to lengthen the QT interval. Sulpiride Thioridazine (especially high risk; withdrawn by the manufacturer for this precise reason) Atypical antipsychotics Amisulpride Quetiapine Overdoses on quetiapine cause QT prolongation in patients with cardiac risks. Risperidone Mild QT prolongation can be caused by risperidone but there are no specific drug warnings associated with this. Sertindole Ziprasidone SSRIs An EKG is recommended before patients are prescribed SSRI agents citalopram and escitalopram if the prescribed dose is above 40 mg or 20 mg per day, respectively. Fluoxetine Paroxetine Sertraline SNRIs Venlafaxine Tricyclic antidepressants Amitriptyline Desipramine Doxepin Imipramine
== Habitat and ecology == Rhizopus oryzae can be found in various soils across the world. For example, it has been found in India, Pakistan, New Guinea, Taiwan, Central America, Peru, Argentina, Namibia, South Africa, Iraq, Somalia, Egypt, Libya, Tunisia, Israel, Turkey, Spain, Italy, Hungary, Czech Republic, Slovakia, Germany, Ukraine, British Isles, and the USA. The soils where R. oryzae has been isolated are varied ranging from grassland, cultivated soils under lupin, corn, wheat, groundnuts, other legumes, sugar canes, rice, citrus plantations, steppe type vegetation, alkaline soils, salt-marshes, farm manure soils, to sewage filled soils. The pH of the soils where the species has been isolated typically range from 6.3 to 7.2. Rhizopus oryzae is often identified as R. arrhizus when isolated from foods. It is found in rotting fruits and vegetables where it is often called R. stolonifer. Unlike the other species such as R. stolonifer, R. oryzae is common in tropical conditions. In East Asia, it is common in peanuts. For instance, there was 21% isolation from peanut kernels from Indonesia. It is present in maize, beans, sorghum, and cowpeas, pecans, hazelnuts, pistachios, wheat, barley, potatoes, sapodillas, and various other tropical foods. Maize meal on which isolates of R. oryzae had been grown was found to be toxic to ducklings and rats, causing growth depression.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.